Fused heterocyclic compounds as peptidase inhibitors

Details Fused heterocyclic compounds as peptidase inhibitors Fused heterocyclic compounds as peptidase inhibitors

2003-08-07

2009-06-16

Solola, Taofiq A (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S173000

Reexamination Certificate

active

07547710

ABSTRACT:
A compound represented by the formula wherein ring A is an optionally substituted 5- to 10-membered aromatic ring; R1and R2are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X and Y are the same or different and each is a bound, —O—, —S—, —SO—, —SO?2#191- or —NR3— (R3is a hydrogen atom or an optionally substituted hydrocarbon group); and L is a divalent hydrocarbon group, or a salt thereof shows a superior peptidase-inhibitory activity and is useful as a prophylactic or therapeutic agent of diabetes and the like.

REFERENCES:
patent: 98/19998 (1998-05-01), None
patent: 01/82925 (2001-11-01), None
patent: 02/062764 (2002-08-01), None
patent: 03/068748 (2003-08-01), None
Sakurai et al., Bull. Chem. Soc. Japan, (1969), vol. 42(1), pp. 220-223.
G. M. Coppola et al.,“1-Aminomethylisoquinoline-4-carboxylates as Novel Dipeptidylpeptidase IV Inhibitors”, Bioorganic & Medicinal Chemistry Letters, vol. 10, 2000, pp. 1555-1558.
K. Augustyns et al., “The Unique Properties of Dipeptidyl-peptidase IV (DPP IV/CD26) and the Therapeutic Potential of DPP IV Inhibitors”, Current Medicinal Chemistry, vol. 6, 1999, pp. 311-327.

Affiliated with

Also associated with

Rating

Fused heterocyclic compounds as peptidase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fused heterocyclic compounds as peptidase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused heterocyclic compounds as peptidase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4085890